Fluzoparib after platinum for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests the PARP inhibitor fluzoparib as a maintenance treatment for women with advanced triple-negative breast cancer whose disease responded or stabilized after platinum-based chemotherapy. The goal is to see if taking fluzoparib daily can delay cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with advanced triple-negative breast cancer (hormone receptor and HER2 negative).
- You have received at least two prior treatments, including one with a platinum drug, and your disease either shrank or stayed stable for at least 6 months on that platinum therapy.
- You have cancer that can be measured on a CT or MRI scan, and it has spread beyond the breast to other parts of the body.
- Your bone marrow, liver, and kidneys are working well enough, and you have recovered from previous treatment side effects.
- You are willing to provide a tumor sample (from a past biopsy or new biopsy) for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether fluzoparib added to standard hormone (endocrine) therapy after early breast cancer surgery can improve outcomes and safety. It may help patients whose tumors are ER-positive, HER2-negative, and a specific SNF3 subtype.
This study tests a combination of two drugs – fluzoparib (a PARP inhibitor) and camrelizumab (an immunotherapy) – given before surgery for early-stage or locally advanced HER2-negative breast cancer in people with an inherited BRCA mutation. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a drug called fluzoparib (a PARP inhibitor) after surgery for early breast cancer in people with specific gene mutations that affect DNA repair. The goal is to see if this drug lowers the chance of cancer coming back.
This trial tests two oral medications given after your first round of chemotherapy. The goal is to see if taking these drugs regularly can keep the cancer from coming back.
This study tests a new maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have finished their first round of chemo and are showing good response. The goal is to see if this treatment helps delay the cancer from coming back.
This trial tests two oral medications (fluzoparib and apatinib) taken daily as maintenance therapy after your ovarian cancer has responded to chemotherapy. The goal is to keep the cancer from returning for as long as possible.
Hear when a new Platinum-sensitive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.